NGeneBio plans third-party allotment of 6,000,000 new shares
NGeneBio filed a rights offering for 6,000,000 new shares through third-party allotment, equal to 37.3% of existing shares. The issue amount is ₩6.0bn, with funds intended as operating funds. The amount equals 28.2% of FY2025 revenue by our calculation.
Key facts
| New shares | 6,000,000 shares |
|---|---|
| New shares as % of existing shares (calculated) | 37.3% |
| Issue amount | ₩6.0bn |
| Main purpose of funds | Operating funds |
| Allocation method | Third-party allotment |
Comparison
| Amount as % of FY2025 revenue (calculated) | 28.2% |
|---|---|
| Revenue 2025 | ₩21.2bn |
| Revenue 2024 | ₩5.7bn |
| Revenue 2023 | ₩4.4bn |
Context
In the 12 months before this filing, the company's rights offering new shares totaled 7,150,000 shares, and potential new shares including this filing equal 81.7% of shares by our calculation.
Key metrics
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 15,150,000 shares |
| Potential new shares, last 12 months | 15,150,000 shares |
| Potential new shares, % of shares | 94.2% |
| Conversion price adjustments, last 12 months | 0 |
Related filings
- NGeneBio to acquire Solar AM Holdings shares for ₩2.0bn
- NGeneBio plans third-party allotment of 2,000,000 new shares
Source: DART (Financial Supervisory Service) · Original filing on DART ↗